Successful, we will replay to you quickly.

OK

Please select the quantity.

OK

Your message is being sent, please wait.

Close

test

Close

Send mail failed, please send again!

Close

Products are for research use only. Not for human use. We do not sell to patients.

Signaling Pathway

Thalidomide

HY-14658

Thalidomide

Thalidomide Chemical Structure

Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF in vivo.

Price and Availability of Thalidomide

  • Select country:
  • America
  • Europe
  • Others
Size Price Stock Quantity
10 mM * 1 mL $88 In-stock
200 mg $80 In-stock
500 mg $150 In-stock
1 g Get quote
5 g Get quote
Size Price Stock Quantity
10 mM * 1 mL €86 In-stock
200 mg €78 In-stock
500 mg €147 In-stock
1 g Get quote
5 g Get quote

Discount Prices Available for Larger Orders.

Inquiry Online

Hide
Salutation:
*Area: Country:
*Customer: *Company Name:
*Email: *Requested quantity:
Remarks:

Your information is safe with us

* Required Fields

Thalidomide Data Sheet

  • Pdf Version Network Version

    DataSheet

Related Compound Libraries

Inhibitor Kit

Biological Activity of Thalidomide

Thalidomide can directly inhibit angiogenesis induced by bFGF or VEGF in vivo.
IC50 value:
Target:
Thalidomide was commonly used therapeutically in the late 1950's; however, it was withdrawn from the market when it was discovered to cause birth defects. More recent research has found Thalidomide to affect key biochemical pathways yielding antiangiogenic and immunomodulatory activities. This compound has been shown to: selectively inhibit tumor necrosis factor-alpha (TNF alpha) biosynthesis and basic fibroblast growth factor (bFGF)-induced angiogenesis, induce apoptosis in human monocytes via a cytochrome c-dependent pathway, and to inhibit HIV-1 replication in a monocytoid (U1) line. These new found uses make Thalidomide an extremely valuable research tool.

Chemical Information

M.Wt 258.23 Storage Please store the product under the recommended conditions in the Certificate of Analysis.
Formula C13H10N2O4
CAS No 50-35-1
Solvent & Solubility

DMSO >20 mg/mL

Preparing Stock Solutions

1 mg 5 mg 10 mg
1 mM 3.8725 mL 19.3626 mL 38.7252 mL
5 mM 0.7745 mL 3.8725 mL 7.7450 mL
10 mM 0.3873 mL 1.9363 mL 3.8725 mL

Clinical Information of Thalidomide

Product Name Sponsor Only Condition Start Date End Date Phase Last Change Date
Thalidomide Millennium Pharmaceuticals Inc Multiple myeloma 30-JUN-07 31-MAY-13 Phase 3 03-JUL-13
Second Military Medical University PLA Multiple myeloma 30-JUN-10 30-JUN-14 Phase 4 13-SEP-13
University of Arkansas Multiple myeloma 30-NOV-06 30-APR-13 Phase 3 14-NOV-13
PETHEMA Foundation Multiple myeloma 31-JAN-07 30-JUN-10 Phase 4 20-SEP-11
University of Cincinnati Uveitis 31-JAN-04 31-AUG-06 Phase 4 10-SEP-13

References on Thalidomide